How much weight loss did petrelintide show?

In the Phase 2 ZUPREME-1 trial (announced March 2026, ~493 participants), petrelintide produced mean weight loss of up to about 10.7% at week 42 versus about 1.7% with placebo. The figure was more modest than the incretins, but at the most effective dose there were no cases of vomiting and no GI-driven discontinuations.

Why does petrelintide's tolerability matter?

Amylin analogues tend to cause fewer gastrointestinal side effects than GLP-1 agonists. Petrelintide's 'placebo-like tolerability' is the basis for positioning it as a gentler, foundational therapy that more people can stay on, or as a combination partner that softens a GLP-1's GI profile.

Can you buy petrelintide as a research compound?

Petrelintide is a proprietary Zealand Pharma molecule and is not catalogued by research-compound suppliers. New-U does not sell petrelintide. The established amylin-analogue research reference is cagrilintide, catalogued as a lyophilised reference peptide, research use only, not for human consumption.

Shop by goal

Popular compounds

Research resources

Certificates of Analysis

Petrelintide (ZP8396): A Research Guide to the Long-Acting Amylin Analogue

Q: What is petrelintide?

Petrelintide (development code ZP8396) is an investigational long-acting amylin analogue from Zealand Pharma, partnered with Roche. It is given as a once-weekly subcutaneous injection and is positioned as a foundational weight-management therapy, used alone or combined with a GLP-1 agonist.

Q: Is petrelintide approved?

No. As of mid-2026 petrelintide has no marketing authorisation anywhere in the world. It completed Phase 2 (ZUPREME-1) and is advancing to Phase 3. The FDA, MHRA and EMA have not approved it.

Short answer: petrelintide (ZP8396) is a long-acting amylin analogue from Zealand Pharma, partnered with Roche, given once weekly. It is the field’s bet that the future is gentler : the Phase 2 ZUPREME-1 trial reported ~ 10.7% mean weight loss at 42 weeks — more modest than the incretins — but with “placebo-like tolerability” (no vomiting, no GI dropouts at the top effective dose). It is positioned as a foundational therapy, alone or combined with a GLP-1. It has no marketing authorisation anywhere as of mid-2026 and is advancing to Phase 3. New-U does not sell petrelintide. Part of our next obesity-research wave overview.

Plain-English summary. Petrelintide is an unapproved, investigational molecule. The FDA, MHRA and EMA have not authorised it. This page is general information, not legal or medical advice; do not use unapproved compounds on people.

What petrelintide actually is

Petrelintide (developmental code ZP8396 ) is a long-acting amylin analogue — a synthetic version of the satiety hormone amylin, engineered for a long half-life so it can be dosed once a week. Where most of the next wave reaches for more mechanisms, petrelintide deliberately does the opposite: it is a clean, single-pathway amylin drug. Zealand Pharma develops it; in 2025 Roche entered an exclusive collaboration to co-develop and co-commercialise it.

The amylin mechanism

Amylin is co-secreted with insulin from pancreatic beta cells and signals fullness. A long-acting amylin analogue:

Activates amylin receptors to promote satiety and slow gastric emptying modestly.

Appears to restore leptin sensitivity , so the body’s own “I’ve eaten enough” signalling works better.

Tends to produce fewer GI side effects than GLP-1 agonism — the basis of petrelintide’s tolerability pitch.

It is the same hormone class as cagrilintide, the amylin component inside CagriSema — which is exactly why amylin analogues are studied both as standalone drugs and as combination partners for GLP-1s.

The ZUPREME-1 Phase 2 evidence

ZUPREME-1 (announced March 2026) was a gender-balanced Phase 2 trial in ~493 people with overweight or obesity, comparing five once-weekly doses of petrelintide against placebo on top of diet and activity. Headlines:

Metric Petrelintide (top dose) Placebo Mean weight loss at 42 weeks up to ~−10.7% ~−1.7% Vomiting at most effective dose None reported — GI-driven discontinuations None —

The investor reaction. ~10.7% is a genuine result, but markets had been primed by incretin numbers in the 20%+ range, so some analysts read ZUPREME-1 as underwhelming on magnitude. The counter-argument is that an amylin drug is not trying to win on raw percentage — it is trying to win on tolerability and durability, as a base layer. Both readings are defensible; the Phase 3 design will test the thesis.

Why “foundational” is the key word

Zealand and Roche position petrelintide as a foundational therapy rather than a maximal one:

As monotherapy — for people who cannot tolerate GLP-1 GI effects, or who want a gentler ramp.

As a combination base — layered with a GLP-1 to add efficacy while the amylin arm keeps the overall GI burden lower. This is the same combination logic as CagriSema, but built from the amylin side.

How petrelintide compares

Compound Mechanism Pitch Status Petrelintide Amylin only Gentler, foundational Phase 3 planned Cagrilintide Amylin only Amylin reference / CagriSema component In combination (CagriSema) CagriSema Amylin + GLP-1 Maximal combination NDA filed Amycretin Amylin + GLP-1 (one molecule) Oral + injectable Phase 3 planned

Petrelintide and research compounds

Petrelintide is a proprietary Zealand Pharma molecule, not a catalogued reference peptide. New-U does not sell petrelintide. The established, verifiable amylin-analogue research reference is:

Cagrilintide — the long-acting amylin-analogue reference peptide, the same hormone class petrelintide belongs to.

It ships as a sealed, lyophilised reference peptide verified to >99% HPLC purity with a per-batch Certificate of Analysis — research use only, not for human consumption .

Frequently Asked Questions

What is petrelintide? Zealand Pharma and Roche’s long-acting amylin analogue (ZP8396), dosed once weekly, positioned as a foundational weight-management therapy.

Is petrelintide approved? No. As of mid-2026 it has no marketing authorisation; it is advancing to Phase 3.

How much weight loss? ~10.7% mean at 42 weeks in ZUPREME-1 — modest versus incretins, but with notably clean GI tolerability.

Why does tolerability matter? Amylin analogues cause fewer GI side effects, so petrelintide is pitched as a gentler base layer, alone or with a GLP-1.

Can I buy petrelintide for research? No — it is proprietary. New-U catalogues the amylin reference cagrilintide instead. Research use only.

Primary sources & further reading

Zealand Pharma — Petrelintide pipeline & ZUPREME-1 Phase 2

Roche — Positive Phase 2 results for petrelintide

U.S. National Library of Medicine — PubMed: petrelintide

ClinicalTrials.gov — petrelintide trial registry

U.S. FDA — FDA (no petrelintide approval as of publication)

External links are provided for research reference only; New-U is not affiliated with the cited organisations and links carry no endorsement either way.

From the Lab - Peptides on LinkedIn & Facebook

Lab-Verified Amylin Research Reference

New-U Research Compounds catalogues cagrilintide — the long-acting amylin-analogue research reference — as sealed 10-vial packs of lyophilised reference peptide, independently verified by Janoshik and Freedom Diagnostics for >99% HPLC purity, with a per-batch Certificate of Analysis. Research use only — not for human consumption.

Research-grade · >99% HPLC purity · COA per lot

Buy research peptides from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.

Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.

Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.

Petrelintide (ZP8396): A Research Guide to the Long-Acting Amylin Analogue

What petrelintide actually is

The amylin mechanism

The ZUPREME-1 Phase 2 evidence

Why “foundational” is the key word

How petrelintide compares

Petrelintide and research compounds

Frequently Asked Questions

Related Reading

Primary sources & further reading

From the Lab - Peptides on LinkedIn & Facebook

Lab-Verified Amylin Research Reference

Buy research peptides from New-U Research Compounds

Shop

Learn

Company

Support

Ways to Pay

Shop by Compound

Shop by Goal

Ships worldwide